Letter to the Editor: ABIDE Model for Predicting Decompensation in Nonalcoholic Fatty Liver Disease‐Related Cirrhosis
Abhinav Anand, Piyush Pathak, Shalimar – 3 December 2020
Abhinav Anand, Piyush Pathak, Shalimar – 3 December 2020
Many HCV-infected patients suffer from decompensated cirrhosis. Aside from appropriate care of their cirrhosis, these patients may benefit from therapy, irrespective of liver transplant candidacy. Providers outside of transplant centers, should be knowledgeable about pertinent aspects of liver transplants for their patients. Finally, several groups have reported unusual genotype subtypes which are less responsive to existing DAA regimens. This webinar is designed for the experienced HCV-treatment provider.Brian Pearlman Brian L.
Ana Garcia Garcia de Paredes, Nicolo Manicardi, Luis Tellez, Luis Ibañez, Felix Royo, Javier Bermejo, Carolina Blanco, Constantino Fondevila, Val Fernandez Lanza, Laura Garcia‐Bermejo, Juan Manuel Falcon‐Perez, Rafael Bañares, Jordi Gracia‐Sancho, Agustin Albillos – 2 December 2020 – Noninvasive staging of decompensated cirrhosis is an unmet clinical need. The aims of this study were to characterize and validate a novel microRNA (miRNA) signature to stage decompensated cirrhosis and predict the portal pressure and systolic cardiac response to nonselective beta‐blockers (NSBBs).
1 December 2020
Jie Guo, Tomohiko Akahoshi, Yukie Mizuta, Masaharu Murata, Sayoko Narahara, Takahito Kawano, Yoshihiro Nagao, Shuo Zhang, Morimasa Tomikawa, Hirofumi Kawanaka, Makoto Hashizume – 1 December 2020 – Hepatic ischemia/reperfusion injury (IRI) is a major complication of liver surgery and transplantation, especially in patients with nonalcoholic steatohepatitis (NASH). The mechanism of NASH susceptibility to IRI has not been fully clarified. We investigated the role of liver‐produced histidine‐rich glycoprotein (HRG) in NASH IRI.
Mattias Lissing, Greg Nowak, René Adam, Vincent Karam, Alexander Boyd, Laurent Gouya, Wouter Meersseman, Espen Melum, Urszula Ołdakowska‐Jedynak, Florian P. Reiter, Jordi Colmenero, Rosario Sanchez, Uta Herden, Janneke Langendonk, Paolo Ventura, Helena Isoniemi, Olivier Boillot, Felix Braun, Stéphanie Perrodin, Elizabeth Mowlem, Staffan Wahlin, European Liver and Intestine Transplant Association – 1 December 2020 – Recurrent attacks of acute intermittent porphyria (AIP) result in poor quality of life and significant risks of morbidity and mortality.
Iván A. González, Hsiang‐Chih Lu, Zahra Alipour, Sakil S. Kulkarni, Janis M. Stoll, Kim H.H. Liss, Louis P. Dehner, Mai He – 30 November 2020 – Centrilobular injury (CLI) is defined as the presence of perivenular mononuclear inflammation, hepatocyte dropout, and extravasated erythrocytes. In pediatric liver allografts, CLI has been associated with advanced fibrosis and chronic rejection (CR). We sought to better characterize the clinicopathologic features of CLI in the setting of T cell–mediated rejection (TCMR) and its association with complement component 4d (C4d) deposition.
Joy Varghese, Selvakumar Malleeswaran, Rajanikanth V. Patcha, Ellango Appusamy, Perumal Karnan, Dharmesh Kapoor, Kota Venugopal, Chandhan Kumar Kedarisetty, Balbir Singh, Prashantha S. Rao, Raghavendra Babu Yalakanti, Ravi Mohanka, Anurag Shrimal, Vinayak Nikam, Karan Kumar, Sunil D. Shenvi, Bhaskaran Pillai Venugopal, Nigel D. Heaton – 30 November 2020
Prashant Bhangui, Sanjiv Saigal, Dheeraj Gautam, Tarun Piplani, Narendra Choudhary, Rohan Chaudhary, Sanjay Yadav, S. Thiagarajan, Amit Rastogi, Neeraj Saraf, Samiran Nundy, A.S. Soin – 30 November 2020 – Conventional selection criteria for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) are based on tumour size/number only, and do not consider vital surrogates of tumor biology such as alpha‐fetoprotein (AFP) and tumor [18F]fluorodeoxyglucose positron emission tomography ([18F]FDG PET) avidity.
May S. Freag, Bumseok Namgung, Maria E. Reyna Fernandez, Ermanno Gherardi, Shiladitya Sengupta, Hae Lin Jang – 29 November 2020 – Nonalcoholic steatohepatitis (NASH), an advanced stage of nonalcoholic fatty liver disease (NAFLD), is a rapidly growing and global health problem compounded by the current absence of specific treatments. A major limiting factor in the development of new NASH therapies is the absence of models that capture the unique cellular structure of the liver microenvironment and recapitulate the complexities of NAFLD progression to NASH.